UNSPSC 51413204: Sildenafil

This classification denotes a cgmp phosphodiesterase inhibitor with the molecular formula C22H30N6O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3M7OB98Y7H, chemically known as 1-((3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1h-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine but generally known as sildenafil, which bears US NIH Compound Identifier 5212. European Medicines Agency schedules Sildenafil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10517MIG.

UNSPSC 51413204 Sildenafil is a Commodity code covering pharmaceutical products supplied to state and local government health and emergency services. State and local procurement under this code focuses on medications for emergency medical services, state pharmacy benefit programs, and multi-jurisdictional cooperative purchasing arrangements. The issuing bodies range from municipal fire rescue departments to state health agencies and multistate cooperative purchasing alliances, reflecting the breadth of government demand for pharmaceutical goods across operational and benefit-administration functions.

Activity appears concentrated in Texas, Florida, and the Upper Midwest through cooperative purchasing vehicles. The City of Tampa's Fire Rescue issued an IFB on April 24, 2026 (response deadline April 8, 2026) for Advanced Life Support Medications including epinephrine, labetalol, adenosine, and diltiazem, with an estimated contract value of $40,000 and SLBE sheltered-market designation offering a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted an RFP on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to supply state and local facilities across participating jurisdictions including Oregon, requiring vendors to distribute through three authorized wholesalers with contract effectiveness July 1, 2026. The Texas Health and Human Services Commission issued an exploratory RFI on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager and group purchasing organization arrangements. Vendors pursuing this code should expect firm-price structures, FDA compliance documentation, expiration-date warranties (typically nine to twelve months minimum shelf life), Safety Data Sheets per OSHA Hazard Communication Standards, and insurance requirements including commercial general liability coverage in the $2 million to $5 million range depending on the solicitation scope.